Matsumoto Fumihiko, Karasawa Kumiko, Itoh Shin, Toda Megumi, Haruyama Takuo, Furukawa Masayuki, Ikeda Katsuhisa
Department of Oto-rhino-laryngology, Juntendo University school of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Anticancer Res. 2006 Sep-Oct;26(5B):3781-6.
This study was designed to evaluate the concomitant use of weekly docetaxel and hyperfractionated radiotherapy for the treatment of head and neck cancer (HNC).
Twenty-five patients with advanced squamous cell HNC were treated with hyperfractionated radiotherapy (72 Gy at 1.2 Gy twice per day) and weekly chemotherapy with docetaxel (10 mg/m2).
Toxicity was significant, with grade 2 to 4 mucositis observed in 100% and lymphopenia in 84%. Seventeen patients (68%) received the full chemotherapy regimen as planned. The initial overall response rate was 88.0%, while the complete response rate was 68.0%. At a median follow-up period of 10 months, the 2-year Kaplan-Meier projected overall survival was 47.3%, and the cause-specific survival was 81.8%.
This study demonstrated that hyperfractionated radiotherapy with weekly docetaxel achieved better initial response than conventional radiotherapy. In addition, the acute toxicity of this regimen was within the acceptable limits of severity.
本研究旨在评估每周使用多西他赛与超分割放疗联合治疗头颈癌（HNC）的效果。
25例晚期鳞状细胞头颈癌患者接受了超分割放疗（每天两次，每次1.2 Gy，共72 Gy）以及每周一次的多西他赛化疗（10 mg/m²）。
毒性反应显著，100%的患者出现2至4级黏膜炎，84%的患者出现淋巴细胞减少。17例患者（68%）按计划接受了完整的化疗方案。初始总体缓解率为88.0%，完全缓解率为68.0%。在中位随访期10个月时，2年的Kaplan-Meier预测总生存率为47.3%，病因特异性生存率为81.8%。
本研究表明，每周使用多西他赛的超分割放疗比传统放疗取得了更好的初始缓解效果。此外，该方案的急性毒性在可接受的严重程度范围内。
